Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2009
08/11/2009CA2358361C Stable compositions for parenteral administration and their use
08/11/2009CA2348732C Human h37 proteins and cdnas encoding the same
08/11/2009CA2335685C Benflumetol derivatives, intermediates thereof and their use against parasitical protozoa and trematodes
08/11/2009CA2335012C Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
08/11/2009CA2331393C Fatty acid analogues for the treatment of primary and secondary restenosis
08/11/2009CA2320120C Benzisoxazole derivatives having d4-antagonistic activity
08/11/2009CA2315890C Rate controlling membranes for controlled drug delivery devices
08/11/2009CA2258503C Lectin compositions and uses thereof
08/11/2009CA2236699C Immunity against actinobacillus pleuropneumoniae's rtx toxins apx
08/11/2009CA2224404C Cell volume-regulated human kinase h-sgk
08/11/2009CA2222552C N-oxides as antibacterial agents
08/08/2009CA2620932A1 Use of antiresorptive compounds to prevent radiation-induced activation of osteoclasts and resulting bone loss
08/06/2009WO2009097614A1 Methods of treating multiple sclerosis by administering pulse dose calcitrol
08/06/2009WO2009097578A1 Oxim derivatives as hsp90 inhibitors
08/06/2009WO2009097567A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
08/06/2009WO2009097490A1 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
08/06/2009WO2009097486A1 OXAZOLE-PYRROLE-PIPERAZINE α-HELIX MIMETIC
08/06/2009WO2009097476A1 NOVEL sEH INHIBITORS AND THEIR USE
08/06/2009WO2009097475A1 NOVEL sEH INHIBITORS AND THEIR USE
08/06/2009WO2009097474A1 Novel seh inhibitors and their use
08/06/2009WO2009097446A1 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
08/06/2009WO2009097443A2 Liquid formulations of compounds active at sulfonylurea receptors
08/06/2009WO2009097416A1 Imidazolylalkyl- pyridines as dbh inhibitors
08/06/2009WO2009097414A1 Use of imidazolylalkyl-pyridines for the treatment of addictive disorders
08/06/2009WO2009097406A1 A method of administering a pde3 inhibitor via titration for the treatment of peripheral arterial disease
08/06/2009WO2009097401A1 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
08/06/2009WO2009097351A2 TAK1-D MEDIATED INDUCTION OF CELL DEATH IN HUMAN CANCER CELLS BY SPECIFIC SEQUENCE SHORT DOUBLE STRANDED RNAs
08/06/2009WO2009097309A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
08/06/2009WO2009097306A1 Substituted pyridazine derivatives which have histamine h3 antagonist activity
08/06/2009WO2009097287A1 Compounds and compositions as kinase inhibitors
08/06/2009WO2009097278A1 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
08/06/2009WO2009097259A2 Use of ibogamine congeners for treating obesity
08/06/2009WO2009097233A1 Imidazopyrazines as protein kinase inhibitors
08/06/2009WO2009097228A2 Composition and method for treating and preventing musculoskeletal and connective tissue disorders
08/06/2009WO2009097223A1 Substituted gamma lactams as therapeutic agents
08/06/2009WO2009097144A1 Molecular probes for pet-imaging of dopamine neurotransmission and neuroendocrine processes in vivo
08/06/2009WO2009097143A1 Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
08/06/2009WO2009097138A1 Antiviral compositions and methods of treatment
08/06/2009WO2009097127A1 Pharmaceutical compositions
08/06/2009WO2009097123A1 Device for in-situ generation of povidone-iodine compositions
08/06/2009WO2009097120A1 Methods using immunomodulatory compounds for modulating level of cd59
08/06/2009WO2009097113A2 Oxazole and thiazole compounds as b-catenin modulators and uses thereof
08/06/2009WO2009097095A2 Methods for treating hematopoietic malignancies
08/06/2009WO2009097014A2 Therapeutic kinase modulators
08/06/2009WO2009096993A1 Antimicrobial n-halogenated amino acid salts
08/06/2009WO2009096941A1 Substituted heterocyclic ethers and their use in cns disorders
08/06/2009WO2009096908A2 Extended-release fluvastatin tablet
08/06/2009WO2009096905A1 Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds
08/06/2009WO2009096817A2 Agent for reducing the degree of acute alcoholic intoxication (inebriation) and the use thereof
08/06/2009WO2009096810A1 Method for producing a water-soluble pharmaceutical composition
08/06/2009WO2009096807A1 Pharmaceutical formulation comprising dicholine salt of succinic acid
08/06/2009WO2009096789A1 Composition for stimulating natural killer cell activity
08/06/2009WO2009096772A1 Composition for stimulating natural killer cell activity
08/06/2009WO2009096655A1 Composition comprising the compound isolated from the flower extract of daphne genkwa for preventing and treating cancer disease and the use thereof
08/06/2009WO2009096616A1 Composition for inhibiting the activity of inositol 1,4,5-triphosphate receptor subtype iii
08/06/2009WO2009096615A1 Composition for preventing or treating brain cancers
08/06/2009WO2009096609A1 Thiazole derivative and use thereof as vap-1 inhibitor
08/06/2009WO2009096581A1 Membrane fusion inhibitor
08/06/2009WO2009096579A1 Nutritional composition for prevention of hyperglycemia
08/06/2009WO2009096564A1 Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
08/06/2009WO2009096560A1 Orally rapidly disintegrating tablet comprising imidafenacin
08/06/2009WO2009096559A1 Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient
08/06/2009WO2009096526A1 Carboxylic acid compound or salt thereof
08/06/2009WO2009096505A1 Agent for improving attention and concentration powers
08/06/2009WO2009096503A1 Benzyl phenyl glucopyranoside derivative
08/06/2009WO2009096487A1 Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
08/06/2009WO2009096455A1 Pharmaceutical composition for treatment of fatty liver diseases
08/06/2009WO2009096435A1 Condensed heterocyclic derivatives and uses thereof
08/06/2009WO2009096377A1 Combined use of angiogenesis inhibitor and taxane
08/06/2009WO2009096354A1 Fentanyl-containing patch for external use
08/06/2009WO2009096349A1 Crystalline cinnamide compounds or salts thereof
08/06/2009WO2009096315A1 Adhesive patch
08/06/2009WO2009096245A1 Pharmaceutical composition and combined agent
08/06/2009WO2009096198A1 Novel biaryl derivative
08/06/2009WO2009096196A1 Method for determination of sensitivity to anti-cancer agent
08/06/2009WO2009096189A1 Marker for determination of sensitivity to anti-cancer agent
08/06/2009WO2009096080A1 Piperidine derivative
08/06/2009WO2009095934A1 Modified release formulations of hmg coa reductase inhibitors
08/06/2009WO2009095923A2 Corroles for neuroprotection and neurorescue
08/06/2009WO2009095887A1 Cationic sirnas, synthesis and use for interfering rna
08/06/2009WO2009095872A2 Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
08/06/2009WO2009095799A2 Coded medications and methods for preparing same for identification and distinguishment
08/06/2009WO2009095798A2 Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis
08/06/2009WO2009095789A1 Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta
08/06/2009WO2009095788A1 Substituted arylamide oxazepinopyrimidone derivatives
08/06/2009WO2009095787A1 Substituted heteroarylamide oxazepinopyrimidone derivatives
08/06/2009WO2009095726A1 Acrylamide derivatives as vanilloid receptor 1 modulators
08/06/2009WO2009095684A1 Pulmonary formulations of triptans
08/06/2009WO2009095634A1 Amorphous forms of retapamulin
08/06/2009WO2009095621A1 Galenic form for the oral transmucosal delivery of triptans
08/06/2009WO2009095588A2 Synthesis of novel neamine derivatives and use thereof as antibacterial agents
08/06/2009WO2009095583A2 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin
08/06/2009WO2009095568A2 Composition for photodynamic skin treatment
08/06/2009WO2009095560A1 Pharmaceutical compositions containing azetidine derivatives
08/06/2009WO2009095555A1 Novel crystalline form vi of agomelatine, method for preparing same and pharmaceutical compositions containing same
08/06/2009WO2009095522A1 Taxanes, precursors thereof and method for obtaining same
08/06/2009WO2009095503A2 Amino acid derivatives used as pharmaceutical substances
08/06/2009WO2009095499A1 Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs
08/06/2009WO2009095454A2 Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients
08/06/2009WO2009095445A1 New second medical use of 3-(2,2,2-trimethylhydrazine)propionate dihydrate
1 ... 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 ... 7860